BioSpace News Archive

IntriCon Corporation today announced that it intends to offer and sell 1,500,000 shares of its common stock in an underwritten public offering.

Q2 2018 Record Billings of $5.2 Million, Up 152% Year over Year

China YCT International Group, Inc. announced its financial results for the three months ended June 30, 2018.

Innovus Pharmaceuticals, Inc. today reported results for the second quarter 2018.

Rockwell Medical, Inc. provided a business update, financial results for the second quarter ended June 30, 2018 and announced the restatement of its financial results for the first quarter ended March 31, 2018.

ContraFect Corporation announced that Cara Cassino, M.D., the Company’s Executive Vice President of Research and Development and Chief Medical Officer, has been invited by the Food and Drug Administration (FDA) to participate in a panel discussion for a public workshop entitled “Development of Non-Traditional Therapies for Bacterial Infections”.

U. S. News & World Report released its 2018-2019 Best Hospitals National Ranking and the Department of Orthopaedic Surgery at Rush University Medical Center (RUMC), consisting of Midwest Orthopaedics at Rush (MOR) physicians, moved from the fifth to the fourth best orthopedic program in the nation.

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company’s medicines and increase focus on reaching patients.

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the U.S. Food & Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for iclaprim, a targeted, Gram-positive investigational antibiotic, for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Creative Medical Technology Holdings, Inc. announced today an update of its corporate activities.